Abstract:The transient receptor potential vanilloid type 1 (TRPV1), a non-selective cation channel, is known for its essential role in the pathogenesis of various pain conditions such as nerve damage induced hyperalgesia, diabetic neuropathy and cancer pain. Therefore, TRPV1 is considered as a promising target for the development of new anti-inflammatory and analgesic drugs. In the present study, a theoretical study on the functionalities of the molecular interactions between 236 active ligands and TRPV1 was carried out, using three-dimensional quantitative structure-activity relationships (3D-QSAR), molecular docking and molecular dynamics (MD) simulation approaches. The ligand-based CoMSIA model (obtained by use of a random division method for splitting the training and test sets) exhibits optimum predictivity (Q(2) = 0.522, R(ncv)(2) = 0.935, R(pred)(2) = 0.839). The results show that the models are useful tools for the prediction of the test sets as well as newly designed structures against TRPV1 activity. In addition, to verify the rationality of the random division method for splitting the dataset, we also used a self-organizing map (SOM) division approach for establishing the QSAR models. Interestingly, the obtained optimal CoMSIA model based on the SOM division exhibits almost the same proper statistical results (Q(2) = 0.521, R(ncv)(2) = 0.929, R(pred)(2) = 0.829) as the random division-derived model, proving the reasonability of both division methods for building the models. The contour plots of molecular fields along with docking and MD simulation have identified several key structural requirements responsible for the activity. The present work provides extremely useful guidelines for future structural modifications of this class of compounds towards the development of superior TRPV1 antagonists. The new computational insights presented in this study are expected to be valuable for the guideline and development of new potent TRPV1 antagonists.

Study of Some Substituted Quinolines as Transient Receptor Potential Vanilloid 1 Inhibitors by the in silico and in vivo Method

Design, Synthesis and Biological Activities of 2,3-Dihydroquinazolin-4(1h)-one Derivatives As TRPM2 Inhibitors.

Rational Design and Validation of a Vanilloid-Sensitive TRPV2 Ion Channel.

Design, Synthesis and Functional Validation of Peptide Inhibitors Based on TRPV1 Ion Channel Agonist RhTx.

In silico research to assist the investigation of carboxamide derivatives as potent TRPV1 antagonists

Design, Synthesis and Biological Evaluation of Novel 2,3,4,9-Tetrahydro-1h-pyrido[3,4-b]indole Triazole Derivatives As Potent TRPV1 Antagonists.

Discovery of Potent and Selective Transient Receptor Potential Vanilloid 1 (TRPV1) Agonists with Analgesic Effects in Vivo Based on the Functional Conversion Induced by Altering the Orientation of the Indazole Core.

Phenylquinoline Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of 1-(2-Phenylquinoline-4-carbonyl)-n-(4-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide.

Synthesis of Carbamide Derivatives Bearing Tetrahydroisoquinoline Moieties and Biological Evaluation As Analgesia Drugs in Mice

Computational discovery, structural optimization and biological evaluation of novel inhibitors targeting transient receptor potential vanilloid type 3 (TRPV3)

Three-Dimensional Quantitative Structure-Activity Relationship Study of Transient Receptor Potential Vanilloid 1 Channel Antagonists Reveals Potential for Drug Design Purposes

Discovery of novel TRPV1 modulators through machine learning‐based molecular docking and molecular similarity searching

Identification of novel selective TRPV3 antagonists based on virtual screening, molecular docking and bioassay

Computational Integration of TRPV4 Antagonists: 3D QSAR, Molecular Docking, Molecular Dynamics Simulations, ADME/Tox, and Retrosynthesis studies

Novel Benzodiazepines Derivatives As Analgesic Modulating for Transient Receptor Potential Vanilloid 1.

Design, synthesis, biological evaluation, and in silico studies of quinoxaline derivatives as potent p38α MAPK inhibitors

<i>N</i>-(3-Acyloxy-2-benzylpropyl)-<i>N</i>‘-[4-(methylsulfonylamino)benzyl]thiourea Analogues: Novel Potent and High Affinity Antagonists and Partial Antagonists of the Vanilloid Receptor

Design, synthesis and biological evaluation of novel analgesic agents targeting both cyclooxygenase and TRPV1

Isoquinolone derivatives as lysophosphatidic acid receptor 5 (LPA5) antagonists: Investigation of structure-activity relationships, ADME properties and analgesic effects

Drug Design, Synthesis and Biological Evaluation of Heterocyclic Molecules as Anti-Inflammatory Agents

Synthesis and Biological Evaluation of Dihydroisoquinoline-2(1H)- Carbothioamide Derivatives As TRPV1 Antagonists